References
- Aaldriks, Ab, A., E. Maartense, H. J., . W. R. Nortier, G. M. Lydia, van der Geest, S. le Cessie, B. C. Tanis, J. E. A. Portielje, P. Ypma, and E. J. Giltay. 2016. Prognostic factors for the feasibility of chemotherapy and the geriatric prognostic index (GPI) as risk profile for mortality before chemotherapy in the elderly. Acta Oncologica (Stockholm, Sweden) 55 (1):15–23. doi:https://doi.org/10.3109/0284186X.2015.1068446.
- Ahles, T. A., A. J. Saykin, W. W. Noll, C. T. Furstenberg, S. Guerin, B. Cole, and L. A. Mott. 2003. The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psycho-Oncology 12 (6):612–19. doi:https://doi.org/10.1002/pon.742.
- Allegra, A., V. Innao, G. Basile, M. Pugliese, A. G. Allegra, N. Pulvirenti, and C. Musolino. 2020. Post-chemotherapy cognitive impairment in hematological patients: Current understanding of chemobrain in hematology. Expert Review of Hematology 13 (April):393–404. doi:https://doi.org/10.1080/17474086.2020.1738213.
- American Cancer Society. 2019. Cancer treatment & survivorship facts & figures 2019–2021. Atlanta: American Cancer Society.
- The American Cancer Society Medical and Editorial Content Team. 2021. Survival rates for breast cancer. SEER= Surveillance, epidemiology, and end results. Accessed January 27, 2021. https://www.cancer.org/cancer/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-survival-rates.html
- American Society of Health System Pharmacists. 2021. Cyclophosphamide. https://medlineplus.gov/druginfo/meds/a682080.html
- Anderson, D. E., S. Kedar, V. R. Bhatt, K. Schmid, S. A. Holstein, and M. Rizzo. 2020. Neurophysiologic and ophthalmic markers of chemotherapy-related cognitive impairment in patients diagnosed with hematologic cancer: A feasibility study. Journal of the Neurological Sciences 410 (March):116644. doi:https://doi.org/10.1016/j.jns.2019.116644.
- Andreotti, C., J. C. Root, T. A. Ahles, B. S. McEwen, and B. E. Compas. 2015. Cancer, coping, and cognition: A model for the role of stress reactivity in cancer-related cognitive decline. Psycho-Oncology 24 (6):617–23. doi:https://doi.org/10.1002/pon.3683.
- Andrykowski, M. A., J. L. Burris, E. Walsh, B. J. Small, and P. B. Jacobsen. 2010. Attitudes toward information about genetic risk for cognitive impairment after cancer chemotherapy: Breast cancer survivors compared with healthy controls. Journal of Clinical Oncology 28 (21):3442–47. doi:https://doi.org/10.1200/JCO.2009.27.826.
- Andryszak, P., M. Wiłkość, B. Żurawski, and P. Izdebski. 2017. Verbal fluency in breast cancer patients treated with chemotherapy. Breast Cancer (Tokyo, Japan) 24 (3):376–83. doi:https://doi.org/10.1007/s12282-016-0713-4.
- Anstey, K. J., K. Sargent-Cox, N. Cherbuin, and P. S. Sachdev. 2015. Self-reported history of chemotherapy and cognitive decline in adults aged 60 and older: The PATH through life project. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences 70 (6):729–35. doi:https://doi.org/10.1093/gerona/glt195.
- Araujo, N., S. Morais, A. R. Costa, R. Braga, A. F. Carneiro, V. T. Cruz, L. Ruano, J. Oliveira, L. P. Figueiredo, S. Pereira, et al. 2021. Cognitive decline in patients with prostate cancer: Study protocol of a prospective cohort, NEON-PC. BMJ Open 11 (2):e043844. doi:https://doi.org/10.1136/bmjopen-2020-04384.
- Argyriou, A. A., K. Assimakopoulos, G. Iconomou, F. Giannakopoulou, and H. P. Kalofonos. 2011. Either called ‘chemobrain’ or ‘chemofog,’ the long-term chemotherapy-induced cognitive decline in cancer survivors is real. Journal of Pain and Symptom Management 41 (1):126–39. doi:https://doi.org/10.1016/j.jpainsymman.2010.04.021.
- Asor, E., and D. Ben-Shachar. 2018. Gene expression dynamics following mithramycin treatment: A possible model for post-chemotherapy cognitive impairment. Clinical and Experimental Pharmacology & Physiology 45 (10):1028–37. doi:https://doi.org/10.1111/1440-1681.12975.
- Avisar, A., Y. River, E. Schiff, G. Bar-Sela, M. Steiner, and E. Ben-Arye. 2012. Chemotherapy-related cognitive impairment: Does integrating complementary medicine have something to add? Review of the literature. Breast Cancer Research and Treatment 136 (1):1–7. doi:https://doi.org/10.1007/s10549-012-2211-5.
- Bar-Sela, G., D. Tauber, I. Mitnik, H. Sheinman-Yuffe, T. Bishara-Frolova, and J. Aharon-Peretz. 2019. Cannabis-related cognitive impairment: A prospective evaluation of possible influences on patients with cancer during chemotherapy treatment as a pilot study. Anti-Cancer Drugs 30 (1):91–97. doi:https://doi.org/10.1097/CAD.
- Baydoun, M., C. Moran, A. McLennan, K.-A. L. Piedalue, D. Oberoi, and L. E. Carlson. 2021. Mindfulness-based interventions in cancer survivors: A systematic review of participants’ adherence to home practice. Patient Preference and Adherence 15 (June):1225–42. doi:https://doi.org/10.2147/PPA.S267064.
- Baydoun, M., D. Oberoi, M. Flynn, C. Moran, A. McLennan, K.-A. L. Piedalue, and L. E. Carlson. 2020. Effects of yoga-based interventions on cancer-associated cognitive decline: A systematic review. Current Oncology Reports 22 (10):100. doi:https://doi.org/10.1007/s11912-020-00960-5.
- Bedard, M., S. Verma, B. Collins, X. Song, and L. Paquet. 2016. Prospective memory impairment in chemotherapy-exposed early breast cancer survivors: Preliminary evidence from a clinical test. Journal of Psychosocial Oncology 34 (4):291–304. doi:https://doi.org/10.1080/07347332.2016.1181133.
- Blommaert, J., G. Schroyen, M. Vandenbulcke, A. Radwan, A. Smeets, R. Peeters, C. Sleurs, P. Neven, H. Wildiers, F. Amant, et al. 2019. Age-dependent brain volume and neuropsychological changes after chemotherapy in breast cancer patients. Human Brain Mapping 40 (17):4994–5010. doi:https://doi.org/10.1002/hbm.24753.
- Blondelle, G., M. Hainselin, Y. Gounden, and V. Quaglino. 2020. Instruments measuring prospective memory: A systematic and meta-analytic review. Archives of Clinical Neuropsychology 35 (5):576–96. doi:https://doi.org/10.1093/arclin/acaa009.
- Bolton, G., and A. Isaacs. 2018. Women’s experiences of cancer-related cognitive impairment, its impact on daily life and care received for it following treatment for breast cancer. Psychology, Health & Medicine 23 (10):1261–74. doi:https://doi.org/10.1080/13548506.2018.1500023.
- Boykoff, N., M. Moieni, and S. K. Subramanian. 2009. Confronting chemobrain: An in-depth look at survivors’ reports of impact on work, social networks, and health care response. Journal of Cancer Survivorship : Research and Practice 3 (4):223–32. doi:https://doi.org/10.1080/13548506.2018.1500023.
- Briones, T. L., and J. Woods. 2011. Chemotherapy-induced cognitive impairment is associated with decreases in cell proliferation and histone modifications. BMC Neuroscience 12 (December):124. doi:https://doi.org/10.1186/1471-2202-12-124.
- Campbell, K. L., K. Zadravec, K. A. Bland, E. Chesley, F. Wolf, and M. C. Janelsins. 2020. The effect of exercise on cancer-related cognitive impairment and applications for physical therapy: Systematic review of randomized controlled trials. Physical Therapy 100 (3):523–42. doi:https://doi.org/10.1093/ptj/pzz090.
- Centers for Disease Control and Prevention. 2020. Information for health care providers. https://www.cdc.gov/cancer/preventinfections/providers.htm#
- Cerulla, N., À. Arcusa, J.-B. Navarro, N. de la Osa, M. Garolera, C. Enero, G. Chico, and L. Fernández-Morales. 2019. Cognitive impairment following chemotherapy for breast cancer: The impact of practice effect on results. Journal of Clinical and Experimental Neuropsychology 41 (3):290–99. doi:https://doi.org/10.1080/13803395.2018.1546381.
- Cerulla, N., À. Arcusa, J.-B. Navarro, M. Garolera, C. Enero, G. Chico, and L. Fernández-Morales. 2017. Role of Taxanes in chemotherapy-related cognitive impairment: A prospective longitudinal study. Breast Cancer Research and Treatment 164 (1):179–87. doi:https://doi.org/10.1007/s10549-017-4240-6.
- Cheng, H., Z. Yang, B. Dong, C. Chen, M. Zhang, Z. Huang, Z. Chen, and K. Wang. 2013. Chemotherapy-induced prospective memory impairment in patients with breast cancer. Psycho-Oncology 22 (10):2391–95. doi:https://doi.org/10.1002/pon.3291.
- Chiang, A. C. A., X. Huo, A. Kavelaars, and C. J. Heijnen. 2019. Chemotherapy accelerates age-related development of tauopathy and results in loss of synaptic integrity and cognitive impairment. Brain, Behavior, and Immunity 79 (July):319–25. doi:https://doi.org/10.1016/j.bbi.2019.04.005.
- Collins, B., J. Mackenzie, G. A. Tasca, C. Scherling, and A. Smith. 2014. Persistent cognitive changes in breast cancer patients 1 year following completion of chemotherapy. Journal of the International Neuropsychological Society : JINS 20 (4):370–79. doi:https://doi.org/10.1017/S1355617713001215.
- Collins, B., J. MacKenzie, G. A. Tasca, C. Scherling, and A. Smith. 2013. Cognitive effects of chemotherapy in breast cancer patients: A dose-response study. Psycho-Oncology 22 (7):1517–2. doi:https://doi.org/10.1002/pon.3163.
- Couvertier-Lebron, C. E., R. Dove, and S. F. Acevedo. 2016. What you do not know could hurt you: What women wish their doctors had told them about chemotherapy side effects on memory and response to alcohol. Breast Cancer : Basic and Clinical Research 10 (December):229–38. doi:https://doi.org/10.4137/BCBCR.S38389.
- Dahlgren, M. K., K. A. Sagar, M. T. Racine, M. W. Dreman, and S. A. Gruber. 2016. Marijuana use predicts cognitive performance on tasks of executive function. Journal of Studies on Alcohol and Drugs 77 (2):298–308. doi:https://doi.org/10.15288/jsad.2016.77.298.
- De Rosa, N., L. D. Corte, A. Giannattasio, P. Giampaolino, C. Di Carlo, and G. Bifulco. 2021. Cancer-related cognitive impairment (CRCI), depression and quality of life in gynecological cancer patients: A prospective study. Archives of Gynecology and Obstetrics 303 (January):1581–88. doi:https://doi.org/10.1007/s00404-020-05896-6.
- Dwek, M.-R., L. Rixon, C. Hurt, A. Simon, and S. Newman. 2017. Is there a relationship between objectively measured cognitive changes in patients with solid tumours undergoing chemotherapy treatment and their health-related quality of life outcomes? A systematic review. Psycho-Oncology 26 (10):1422–32. doi:https://doi.org/10.1002/pon.4331.
- Eide, S., and Z.-P. Feng. 2020. Doxorubicin chemotherapy-induced ‘chemo-brain’: Meta-Analysis. European Journal of Pharmacology 881 (August):173078. doi:https://doi.org/10.1016/j.ejphar.2020.173078.
- El-Agamy, S., A. Emad, K. Abdel-Aziz, A. Esmat, and S. S. Azab. 2019. Chemotherapy and cognition: Comprehensive review on doxorubicin-induced chemobrain. Cancer Chemotherapy and Pharmacology 84 (1):1–14. doi:https://doi.org/10.1007/s00280-019-03827-0.
- Fardell, J. E., J. Vardy, I. N. Johnston, and G. Winocur. 2011. Chemotherapy and cognitive impairment: Treatment options. Clinical Pharmacology and Therapeutics 90 (3):366–76. doi:https://doi.org/10.1038/clpt.2011.112.
- Ferguson, R. J., B. C. McDonald, A. J. Saykin, and T. A. Ahles. 2007. Brain structure and function differences in monozygotic twins: Possible effects of breast cancer chemotherapy. Journal of Clinical Oncology 25 (25):3866–70. doi:https://doi.org/10.1200/JCO.2007.10.8639.
- Fernandez, H. R., A. Varma, S. A. Flowers, and G. W. Rebeck. 2020. Cancer chemotherapy related cognitive impairment and the impact of the Alzheimer’s disease risk factor APOE. Cancers 12:12. doi:https://doi.org/10.3390/cancers12123842.
- Fischer, B. 2019. Breast cancer plus adjuvant chemotherapy- related cognitive impairment: A case study. Neurocase 25 (3–4):138–44. doi:https://doi.org/10.1080/13554794.2019.1627374.
- Fliessbach, K., H. Urbach, C. Helmstaedter, H. Pels, A. Glasmacher, J. A. Kraus, T. Klockgether, I. Schmidt-Wolf, and U. Schlegel. 2003. Cognitive performance and magnetic resonance imaging findings after high-dose systemic and intraventricular chemotherapy for primary central nervous system lymphoma. Archives of Neurology 60 (4):563–68. doi:https://doi.org/10.1001/archneur.60.4.563.
- Floyd, R., A. H. Dyer, and S. P. Kennelly. 2021. Non-pharmacological interventions for cognitive impairment in women with breast cancer post-chemotherapy: A systematic review. Journal of Geriatric Oncology 12 (March):173–81. doi:https://doi.org/10.1016/j.jgo.2020.05.012.
- Geraghty, A. C., E. M. Gibson, R. A. Ghanem, J. J. Greene, A. Ocampo, A. K. Goldstein, L. Ni, T. Yang, R. M. Marton, S. P. Paşca, et al. 2019. Loss of adaptive myelination contributes to methotrexate chemotherapy-related cognitive impairment. Neuron 103 (2):250. doi:https://doi.org/10.1016/j.neuron.2019.04.032.
- Gokal, K., F. Munir, S. Ahmed, K. Kancherla, and D. Wallis. 2018. Does walking protect against decline in cognitive functioning among breast cancer patients undergoing chemotherapy? Results from a small randomised controlled trial. PloS One 13 (11):e0206874. doi:https://doi.org/10.1371/journal.pone.0206874.
- Gothe, N. P., E. D. Erlenbach, S. L. Streeter, and L. Lehovec. 2020. Effects of yoga, aerobic, and stretching and toning exercises on cognition in adult cancer survivors: Protocol of the STAY Fit pilot randomized controlled trial. Trials 21 (1):792. doi:https://doi.org/10.1186/s13063-020-04723-2.
- Gutenkunst, S. L., J. L. Vardy, H. M. Dhillon, and M. L. Bell. 2021. Correlates of cognitive impairment in adult cancer survivors who have received chemotherapy and report cognitive problems. Supportive Care in Cancer 29 (3):1377–86. doi:https://doi.org/10.1007/s00520-020-05616-5.
- Guttmann, D. H. 2019. Clearing the fog surrounding chemobrain. Cell 176 (1–2):2–4. doi:https://doi.org/10.1016/j.cell.2018.12.027.Co
- Hardy, S. J., K. R. Krull, J. S. Wefel, and M. Janelsins.2018. Cognitive changes in cancer survivors. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 38: 795–806. doi:https://doi.org/10.1200/EDBK_201179.
- Harvard University. 2021. Key concepts: Executive function and self regulation. https://developingchild.harvard.edu/science/key-concepts/executive-function/
- Henneghan, A. M., K. Van Dyk, T. Kaufmann, R. Harrison, C. Gibbons, C. Heijnen, and S. R. Kesler. 2021. Measuring self-reported cancer-related cognitive impairment: Recommendations from the Cancer Neuroscience Initiative Working Group. Journal of the National Cancer Institute (February). doi:https://doi.org/10.1093/jnci/djab027.
- Hess, L. M., H. Q. Huang, A. L. Hanlon, W. R. Robinson, R. Johnson, S. K. Chambers, R. S. Mannel, L. Puls, S. A. Davidson, M. Method, et al. 2015. Cognitive function during and six months following chemotherapy for front-line treatment of ovarian, primary peritoneal or fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group Study. Gynecologic Oncology 139 (3):541–45. doi:https://doi.org/10.1016/j.ygyno.2015.10.003.
- Hormone Therapy. 2020. Hormone therapy linked to cognitive decline. Cancer Discovery 10 (7):896. doi:https://doi.org/10.1158/2159-8290.CD-NB2020-042.
- Huehnchen, P., A. van Kampen, W. Boehmerle, and M. Endres. 2020. Cognitive impairment after cytotoxic chemotherapy. Neuro-Oncology Practice 7 (1):11–21. doi:https://doi.org/10.1093/nop/npz052.
- Ibrahim, E. Y., I. Domenicano, K. Nyhan, M. Elfil, S. S. Mougalian, B. Cartmel, and B. E. Ehrlich. 2021. Cognitive effects and depression associated with taxane-based chemotherapy in breast cancer survivors: A meta-analysis. Frontiers in Oncology 11 (April):642382. doi:https://doi.org/10.3389/fonc.2021.642382.
- Iiumura, Y., T. Kurokawa, M. Nojima, Y. Kanemoto, K. Yazawa, G. Tsurita, and S. Kuroda. 2020. Potential thiamine deficiency and neurological symptoms in patients receiving chemotherapy for gastrointestinal cancer. International Journal of Clinical Pharmacology and Therapeutics 58 (3):139–45. doi:https://doi.org/10.5414/CP203602.
- Jacobs, W., E. Das, and S. B. Schagen. 2017. Increased cognitive problem reporting after information about chemotherapy-induced cognitive decline: The moderating role of stigma consciousness. Psychology & Health 32 (1):78–93. doi:https://doi.org/10.1080/08870446.2016.1244535.
- Janelsins, M. C., C. E. Heckler, L. J. Peppone, T. A. Ahles, S. G. Mohile, K. M. Mustian, O. Palesh, A. M. O’Mara, L. M. Minasian, A. M. Williams, et al. 2018. Longitudinal trajectory and characterization of cancer-related cognitive impairment in a nationwide cohort study. Journal of Clinical Oncology 36 (32):3231–39. doi:https://doi.org/10.1200/JCO.2018.78.6624.
- Janelsins, M. C., C. E. Heckler, L. J. Peppone, C. Kamen, K. M. Mustian, S. G. Mohile, A. Magnuson, I. R. Kleckner, J. J. Guido, K. L. Young, et al. 2017. Cognitive complaints in survivors of breast cancer after chemotherapy compared with age-matched controls: An analysis from a nationwide, multicenter, prospective longitudinal study. Journal of Clinical Oncology 35 (5):506–14. doi:https://doi.org/10.1200/JCO.2016.68.5826.
- Kesler, S. R., F. Chris Bennett, M. L. Mahaffey, and D. Spiegel. 2009. Regional brain activation during verbal declarative memory in metastatic breast cancer. Clinical Cancer Research 15 (21):6665–73. doi:https://doi.org/10.1158/1078-0432.CCR-09-1227.
- Khan, M. A., K. Garg, D. Bhurani, and N. B. Agarwal. 2016. Early manifestation of mild cognitive impairment in B-Cell Non-Hodgkin’s lymphoma patients receiving CHOP and Rituximab-CHOP chemotherapy. Naunyn-Schmiedeberg’s Archives of Pharmacology 389 (12):1253–65. doi:https://doi.org/10.1007/s00210-016-1290-y.
- Khan, O. F., E. Cusano, S. Raissouni, M. Pabia, J. Haeseker, N. Bosma, J. J. Ko, H. Li, A. Kumar, M. M. Vickers, et al. 2019. Immediate-term cognitive impairment following intravenous (IV) chemotherapy: A prospective pre-post design study. BMC Cancer 19 (1):150. doi:https://doi.org/10.1186/s12885-019-5349-2.
- Kim, H.-J., A. M. Barsevick, A. Chan, and J.-W. Chae. 2018. Chemotherapy-associated cognitive impairments in Korean cancer patients: Risk factors and functional outcome. Psycho-Oncology 27 (8):1995–2001. doi:https://doi.org/10.1002/pon.4759.
- Kim, H.-J., S.-O. Jung, H. Kim, and I. Abraham. 2020. Systematic review of longitudinal studies on chemotherapy-associated subjective cognitive impairment in cancer patients. Psycho-Oncology 29 (4):617–31. doi:https://doi.org/10.1002/pon.5339.
- Kingma, A., R. I. Van Dommelen, E. L. Mooyaart, J. T. Wilmink, B. G. Deelman, and W. A. Kamps. 2002. No major cognitive impairment in young children with acute lymphoblastic leukemia using chemotherapy only: A prospective longitudinal study. Journal of Pediatric Hematology/Oncology 24 (2):106–14. doi:https://doi.org/10.1097/00043426-200202000-00010.
- Lange, M., N. Heutte, S. Noal, O. Rigal, J.-E. Kurtz, C. Lévy, D. Allouache, C. Rieux, J. Lefel, B. Clarisse, et al. 2019. Cognitive changes after adjuvant treatment in older adults with early-stage breast cancer. The Oncologist 24 (1):62–68. doi:https://doi.org/10.1634/theoncologist.2017-0570.
- Lange, M., and F. Joly. 2017. How to identify and manage cognitive dysfunction after breast cancer treatment. Journal of Oncology Practice 13 (12):784–90. doi:https://doi.org/10.1200/JOP.2017.026286.
- Leinert, E., L. Schwentner, M. Blettner, A. Wöckel, R. Felberbaum, F. Flock, T. Kühn, M. D. Denkinger, W. Janni, R. Kreienberg, et al. 2019. Association between cognitive impairment and guideline adherence for application of chemotherapy in older patients with breast cancer: Results from the prospective multicenter BRENDA II study. The Breast Journal 25 (May):386–92. doi:https://doi.org/10.1111/tbj.
- Li, W., C. Gan, Y. Lv, S. Wang, and H. Cheng. 2017. Chemotherapy-induced prospective memory impairment in breast cancer patients with different hormone receptor expression. Medicine 96 (13):e6514. doi:https://doi.org/10.1097/MD.0000000000006514.
- Liu, Z., X. Han, C. Tian, J. Chen, L. Lei, Q. Liang, X. Lv, S. Tang, and P. Ning. 2018. A study on the relationship between chemotherapy-induced cognitive impairment and age in patients with breast cancer. Journal of B.U.ON 23 (6):1601–05.
- Mayo, S. J., S. B. Rourke, E. G. Atenafu, R. Vitorino, C. Chen, and J. Kuruvilla. 2021. Computerized cognitive training in post-treatment hematological cancer survivors: A feasibility study. Pilot and Feasibility Studies 7 (1):36. doi:https://doi.org/10.1186/s40814-021-00778-3.
- McAllister, T. W., T. A. Ahles, A. J. Saykin, R. J. Ferguson, B. C. McDonald, L. D. Lewis, L. A. Flashman, and C. H. Rhodes. 2004. Cognitive effects of cytotoxic cancer chemotherapy: Predisposing risk factors and potential treatments. Current Psychiatry Reports 6 (5):364–71. doi:https://doi.org/10.1007/s11920-004-0023-y.
- Meacham, J. A., and B. Leiman. 1982. Remembering to perform future actions. In Memory observed: Remembering in natural contexts, ed. U. Neisser, 327–36. San Francisco: Freeman.
- Meyer, F. 2021. Tips for managing chemobrain. Dana-Farber Cancer Institute, Health Library. https://www.dana-farber.org/health-library/articles/tips-for-managing-chemobrain/ Accessed September 21, 2021
- Mohile, S. G., W. Dale, M. R. Somerfield, M. A. Schonberg, C. M. Boyd, P. S. Burhenn, B. Canin, H. J. Cohen, H. M. Holmes, J. O. Hopkins, et al. 2018. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology. Journal of Clinical Oncology 36 (22):2326–47. doi:https://doi.org/10.1200/JCO.2018.78.8687.
- Morean, D. F., L. O’Dwyer, and L. R. Cherney. 2015. Therapies for cognitive deficits associated with chemotherapy for breast cancer: A systematic review of objective outcomes. Archives of Physical Medicine and Rehabilitation 96 (10):1880–97. doi:https://doi.org/10.1016/j.apmr.2015.05.012.
- National Cancer Institute. 2017. Understanding “chemobrain” and cognitive impairment after cancer treatment. https://www.cancer.gov/about-cancer/treatment/research/understanding-chemobrain Accessed September 21, 2021
- National Cancer Institute. Surveillance Research Program. 2021. Cancer stat facts: Female breast cancer. https://seer.cancer.gov/statfacts/html/breast.html Accessed September 21, 2021
- Ng, T., X. Y. Phey, H. L. Yeo, M. Shwe, Y. X. Gan, R. Ng, H. K. Ho, and A. Chan. 2018. Impact of adjuvant anthracycline-based and taxane-based chemotherapy on plasma VEGF levels and cognitive function in breast cancer patients: A longitudinal study. Clinical Breast Cancer 18 (5):e927–37. doi:https://doi.org/10.1016/j.clbc.2018.03.016.
- O’Farrell, E., J. MacKenzie, and B. Collins. 2013. Clearing the air: A review of our current understanding of Chemo Fog. Current Oncology Reports 15 (3):260–69. doi:https://doi.org/10.1007/s11912-013-0307-7.
- Oberste, M., N. Schaffrath, K. Schmidt, W. Bloch, E. Jäger, K. Steindorf, P. Hartig, N. Joisten, and P. Zimmer. 2018. Protocol for the ‘chemobrain in motion - study’ (CIM - Study): A randomized placebo-controlled trial of the impact of a high-intensity interval endurance training on cancer related cognitive impairments in women with breast cancer receiving first-line chemotherapy. BMC Cancer 18 (1):1071. doi:https://doi.org/10.1186/s12885-018-4992-3.
- Oh, G. H., C.-W. Yeom, E.-J. Shim, D. Jung, K.-M. Lee, K.-L. Son, W.-H. Kim, J. Y. Moon, S. Jung, T.-Y. Kim, et al. 2020. The effect of perceived social support on chemotherapy-related symptoms in patients with breast cancer: A prospective observational study. Journal of Psychosomatic Research 130 (March):109911. doi:https://doi.org/10.1016/j.jpsychores.2019.109911.
- Oh, P.-J. 2017. Predictors of cognitive decline in people with cancer undergoing chemotherapy. European Journal of Oncology Nursing 27 (April):53–59. doi:https://doi.org/10.1016/j.ejon.2016.12.007.
- Oláh, C., Z. Kardos, M. Andrejkovics, E. Szarka, K. Hodosi, A. Domján, M. Sepsi, A. Sas, L. Kostyál, K. Fazekas, et al. 2020. Assessment of cognitive function in female rheumatoid arthritis patients: Associations with cerebrovascular pathology, depression and anxiety. Rheumatology International 40 (4):529–40. doi:https://doi.org/10.1007/s00296-019-04449-8.
- Paquet, L., S. Verma, B. Collins, A. Chinneck, M. Bedard, and X. Song. 2018. Testing a novel account of the dissociation between self-reported memory problems and memory performance in chemotherapy-treated breast cancer survivors. Psycho-Oncology 27 (1):171–77. doi:https://doi.org/10.1002/pon.4389.
- Park, J.-H., Y. S. Jung, Y.-M. Jung, and S. H. Bae. 2019. The role of depression in the relationship between cognitive decline and quality of life among breast cancer patients. Supportive Care in Cancer 27 (7):2707–14. doi:https://doi.org/10.1007/s00520-018-4546-x.
- Psychology Today. 2021. What strategies can help strengthen executive function? https://www.psychologytoday.com/us/basics/executive-function#improving-executive-function Accessed September 21, 2021
- Raffa, R. B. 2013. Cancer ‘survivor-care’: II. Disruption of prefrontal brain activation top-down control of working memory capacity as possible mechanism for chemo-fog/brain (Chemotherapy-associated cognitive impairment). Journal of Clinical Pharmacy and Therapeutics 38 (4):265–68. doi:https://doi.org/10.1111/jcpt.12071.
- Rodríguez Martín, B., E. J. Fernández Rodríguez, M. I. R. Galve, and J. J. C. Hernández. November 2020. Study of chemotherapy-induced cognitive impairment in women with breast cancer. International Journal Environmental Research and Public Health 17(23) nopagination doi:https://doi.org/10.3390/ijerph17238896. Accessed September 21, 2021.
- Saha, P., and N. Sen. 2019. Tauopathy: A common mechanism for neurodegeneration and brain aging. Mechanisms of Ageing and Development 178:72–79. doi:https://doi.org/10.1016/j.mad.2019.01.007.
- Schagen, S. B., and F. S. A. M. Van Dam. 2006. Does cognitive impairment after chemotherapy for breast cancer improve over time or does practice make perfect? Journal of Clinical Oncology 24 (32):5170–71. doi:https://doi.org/10.1200/JCO.2006.07.8303.
- Schrauwen, W., J. Van De Cavey, G. Vingerhoets, S. Vanheule, R. Van Den Broecke, and H. Denys. 2020. Heterogeneous response of chemotherapy-related cognitive decline in patients with breast cancer: A prospective study.Journal of the International Neuropsychological Society: JINS26 (8):806–14. doi:https://doi.org/10.1017/S1355617720000296.
- Seow, H., T. Stevens, L. C. Barbera, F. Burge, K. McGrail, K. K. W. Chan, S. J. Peacock, R. Sutradhar, and D. M. Guthrie. 2021. Trajectory of psychosocial symptoms among home care patients with cancer at end-of-life. Psycho-Oncology 30 (1):103–10. doi:https://doi.org/10.1002/pon.5559.
- Shari, N. I., N. Z. Zainal, and C. G. Ng. 2020 December. Effects of brief acceptance and commitment therapy (ACT) on subjective cognitive impairment in breast cancer patients undergoing chemotherapy. Journal of Psychosocial Oncology 1–30. doi:https://doi.org/10.1080/07347332.2020.1856283.
- Stankus, T. 2008. Can the brain be trained? Comparing the literature on the use of EEG biofeedback/neurofeedback as an alternative or complementary therapy for attention deficit hyperactivity disorder (ADHD). Behavioral & Social Sciences Librarian 26 (4):20–56. doi:https://doi.org/10.1080/01639260802031556.
- Stewart, A., B. Collins, J. Mackenzie, E. Tomiak, S. Verma, and C. Bielajew. 2008. The cognitive effects of adjuvant chemotherapy in early stage breast cancer: A prospective study. Psycho-Oncology 17 (2):122–30. doi:https://doi.org/10.1002/pon.1210.
- Turrina, S., F. Gibelli, and D. De Leo. 2020. Chemotherapy-induced cognitive impairment from the forensic medicine perspective: A review of the updated literature. Journal of Forensic and Legal Medicine 76 (November):102070. doi:https://doi.org/10.1016/j.jflm.2020.102070.
- Underwood, E. A., K. J. Jerzak, G. Lebovic, P. A. Rochon, C. Elser, K. I. Pritchard, and M. C. Tierney. 2019. Cognitive effects of adjuvant endocrine therapy in older women treated for early-stage breast cancer: A 1-year longitudinal study. Supportive Care in Cancer 27 (8):3035–43. doi:https://doi.org/10.1007/s00520-018.
- Van der Gucht, K., M. Melis, S. Ahmadoun, A. Gebruers, A. Smeets, M. Vandenbulcke, H. Wildiers, P. Neven, P. Kuppens, F. Raes, et al. 2020. A mindfulness-based intervention for breast cancer patients with cognitive impairment after chemotherapy: Study protocol of a three-group randomized controlled trial. Trials March, 290. doi: https://doi.org/10.1186/s13063-020-4204-8 21.
- van der Plas, E., A. J. Modi, C. K. Li, K. R. Krull, and Y. T. Cheung. 2021 April. Cognitive impairment in survivors of pediatric acute lymphoblastic leukemia treated with chemotherapy only. Journal of Clinical Oncology JCO2002322. doi:https://doi.org/10.1200/JCO.20.02322.
- Walczak, P., and M. Janowski. 2019. Chemobrain as a product of growing success in chemotherapy - Focus on Glia as both a victim and a cure. Neuropsychiatry 9 (1):2207–16. doi:https://doi.org/10.4172/Neuropsychiatry.1000565.
- Wefel, J. S., A. K. Saleeba, A. U. Buzdar, and C. A. Meyers. 2010. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer 116 (14):3348–56. doi:https://doi.org/10.1002/cncr.25098.
- Whitney, K. A., P. H. Lysaker, A. R. Steiner, J. N. Hook, D. D. Estes, and N. H. Hanna. 2008. Is ‘chemobrain’ a transient state? A prospective pilot study among persons with non-small cell lung cancer. The Journal of Supportive Oncology 6 (7):313–21.
- Yamamoto, S., E. Masutani, and H. Arao. 2020. Self-reported cognitive decline in Japanese patients with breast cancer treated with endocrine therapy. Breast Cancer (Tokyo, Japan) 27 (4):670–82. doi:https://doi.org/10.1007/s12282-020-01062-7.
- Zhou, S.-P., S.-D. Fei, -H.-H. Han, -J.-J. Li, S. Yang, and C.-Y. Zhao. 2021 February. A prediction model for cognitive impairment risk in colorectal cancer after chemotherapy treatment. BioMed Research International 6666453. doi:https://doi.org/10.1155/2021/6666453.